Home Alzheimer’s Disease Brain Metastases Associated With Metastatic RCC Demonstrate Response to Cabozantinib

Brain Metastases Associated With Metastatic RCC Demonstrate Response to Cabozantinib

Significant intracranial and extracranial responses were reported with the use of cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (RCC) and brain metastases.

Results showed that in patients with uncontrolled brain metastases at baseline (n = 25) who received cabozantinib, the intracranial response rate was 61% (95% CI, 39%-80%); this comprised a 13% complete response (CR) rate and a 48% partial response (PR) rate. Thirty percent and 9% of patients experienced stable disease (SD) and progressive disease (PD), respectively.

In those who had controlled brain disease at baseline (n = 44), the intracranial response rate was 57% (95% CI, 41%-72%), which included all PRs. The SD and PD rates were 31% and 12%, respectively.

“This is the largest cohort of patients with metastatic renal cell carcinoma with concomitant brain metastases treated by cabozantinib,” lead…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments